Indicaton
Milestone: IND enabling studies expected H2 2023
We are developing metabotropic glutamate receptor subtype 7, or mGlu7 NAM as a novel orally available treatment to reduce fear memory in PTSD. This is a disorder that can lead to intense fear and anxiety.
